Study of Clinical Performance and Safety of Treatments in Degenerative Meniscopathy With Injection of Polynucleotides

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-10-26

Study Completion Date

2024-07-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a non-randomized multicentre study for the evaluation of the clinical performance and safaty of the augmentation-to-surgery and conservative treatments for the degenerative meniscopathies, with injection of polynucleotide gel.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Intra-operative Injection of Autologous Conditioned Plasma (ACP) Following Partial Meniscectomy

NCT02872753

Meniscectomy

COMPLETED PHASE4

Geniculate Artery Embolization for Knee Pain Secondary to Osteoarthritis (OA)

NCT03362957

Osteo Arthritis Knee

COMPLETED NA

Degenerative Meniscus Without Osteoarthritis : Arthroscopic Partial Menisectomy Versus Platelet Rich Plasma (APM-PRP)

NCT04972331

Meniscectomy Platelet-Rich Plasma Meniscus; Degeneration

UNKNOWN NA

Follow-up Study of Chondrogen® Delivered by Intra-Articular Injection Following Meniscectomy

NCT00702741

Recovery Following Partial Medial Meniscectomy

COMPLETED PHASE1/PHASE2

A Phase I/II Study of Chondrogen Delivered by Intra-Articular Injection Following Meniscectomy

NCT00225095

Recovery Following Partial Medial Meniscectomy

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Meniscal tear plays a significant role among the multitude of ethiologies of knee pain. In the setting of chronic meniscus degeneration, healing potential remains low due to a vascular penetration of less than one-third of the adult meniscus. Currently, both conservative and surgical modalities can be utilized in the treatment of the painful degenerative menisci, and no gold standard treatment has been identified. Polynucleotide gel Condrotide® is a polynucleotide solution, used in case of degenerative painful join pathologies, favouring the physiological mechanism of joint repair because of the capacity to normalize the viscosity of synovial fluid and supposed to improve the joint trophism. The present study aims at evaluating the capacity of the polynucleotide gel injection to stimulate healing and slow down progression of meniscal degeneration, through augmentation-to-surgery and conservative treatments for the degenerative meniscopathies.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Meniscus Tear Meniscus Lesion

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Treatment A (augmentation-to-surgery): subjects surgically treated with partial meniscectomy combined with an intraarticular and intra-meniscal injection of polynucleotide gel.

Treatment B (conservative): subjects treated with three injections session of polynucleotide gel.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm A: augmentation to surgery

Patients will be surgically treated with partial meniscectomy combined with an intraarticular and intra-meniscal injection of polynucleotide gel, during an arthroscopic procedure. After 6 weeks the patients attend a second injection session, during an ambulatorial visit. At 8 weeks from the surgery the patients attend the third ambulatorial injection session

Group Type EXPERIMENTAL

partial meniscectomy

Intervention Type PROCEDURE

Arthroscopic procedure

Condrotide® (polynucleotides gel: class III medical device)

Intervention Type DEVICE

Condrotide® Polynucleotide gel is a joint lubricating and viscosizing agent, given by intraarticular and intra-meniscal injection

Arm B: conservative treatment

The patients are going to receive three injections session (polynucleotide gel) performed with a time interval of 2 weeks.

Group Type EXPERIMENTAL

Condrotide® (polynucleotides gel: class III medical device)

Intervention Type DEVICE

Condrotide® Polynucleotide gel is a joint lubricating and viscosizing agent, given by intraarticular and intra-meniscal injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

partial meniscectomy

Arthroscopic procedure

Intervention Type PROCEDURE

Condrotide® (polynucleotides gel: class III medical device)

Condrotide® Polynucleotide gel is a joint lubricating and viscosizing agent, given by intraarticular and intra-meniscal injection

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female subjects with age between 18 and 65 years
2. Presence of symptomatic degenerative meniscus tear
3. Presence of one of the following unilateral symptoms: pain, catching, or locking of the knee
4. Non responsive to physical therapy for at least 3-4 weeks
5. Be in neutral alignment +/- 5 degrees of the mechanical axis
6. Subject must be physically and mentally willing and able to comply with the study follow-up schedule
7. Subject must sign Ethic committe approved informed consent
8. Subject is willing and able to comply with all study procedures, including visits and diagnostic procedures

Exclusion Criteria

1. Radiographic osteoarthritis of the knee in any compartment greater than Kellgren-Lawrence (KL) grade 3.
2. Presence of bone marrow edema (BME) at the index knee.
3. Presence of knee instability.
4. Have a varus or valgus knee deformity \> 5 degrees.
5. Have meniscal roots tears.
6. Have discoid meniscus.
7. Have patella instability or non-anatomically positioned patella.
8. Have a knee flexion contracture \> 10 degrees.
9. Be unable to flex the knee to 90 degrees.
10. Have a leg length discrepancy causing a noticeable limp.
11. Have an active infection or tumor.
12. Have any type of knee joint inflammatory disease including Sjogren's syndrome.
13. Have neuropathic knee osteoarthropathy, also known as Charcot joint.
14. Any disorder or impairment that would interfere with evaluation of outcomes measures, such as neurological, degenerative muscular, psychiatric or cognitive conditions.
15. Participation to another clinical trial or clinical investigation in the previous 3 months.
16. BMI \> 35.
17. Prior knee arthroscopy within 6 months of study enrolment.
18. Unable to have an MRI scan.
19. Known allergy, sensitivity or intolerance to any of the components of the investigational device or to products originating from fish.
20. Positive history of human immunodeficiency virus antibodies, hepatitis B surface antigen or hepatitis C virus antibodies.
21. Autoimmune diseases, rheumatoid disease eg. Lupus erythematosus.
22. The subject is currently being treated with radiation and or chemotherapy.
23. Previous or ongoing alcohol abuse or dependence, use of illicit drugs within 1 year prior to enrolment.
24. Patients who are pregnant or planning to become pregnant during the planned period of participation in the study or who are breastfeeding. Women of child-bearing age must consent to use and actually make use of a highly effective contraceptive method, considered acceptable by the investigator, for the whole study duration.
25. Does not agree to participate.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No